Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Johnson and Johnson
Moodys
Boehringer Ingelheim
Harvard Business School

Last Updated: July 2, 2020

DrugPatentWatch Database Preview

Brivaracetam - Generic Drug Details

» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for brivaracetam and what is the scope of freedom to operate?

Brivaracetam is the generic ingredient in one branded drug marketed by Ucb Inc and is included in three NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Brivaracetam has one hundred and forty-six patent family members in forty-two countries.

One supplier is listed for this compound.

Summary for brivaracetam
International Patents:146
US Patents:3
Tradenames:1
Applicants:1
NDAs:3
Suppliers / Packagers: 1
Bulk Api Vendors: 29
Clinical Trials: 35
Patent Applications: 586
DailyMed Link:brivaracetam at DailyMed
Recent Clinical Trials for brivaracetam

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of MinnesotaPhase 1/Phase 2
PRA Health SciencesPhase 2/Phase 3
Utrecht UniversityPhase 2/Phase 3

See all brivaracetam clinical trials

Pharmacology for brivaracetam
Mechanism of ActionEpoxide Hydrolase Inhibitors
Paragraph IV (Patent) Challenges for BRIVARACETAM
Tradename Dosage Ingredient NDA Submissiondate
BRIVIACT SOLUTION;INTRAVENOUS brivaracetam 205837 2020-05-12
BRIVIACT SOLUTION;ORAL brivaracetam 205838 2020-05-12

US Patents and Regulatory Information for brivaracetam

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ucb Inc BRIVIACT brivaracetam SOLUTION;ORAL 205838-001 May 12, 2016 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-003 May 12, 2016 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-001 May 12, 2016 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-005 May 12, 2016 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-004 May 12, 2016 RX Yes No   Start Trial   Start Trial   Start Trial
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-004 May 12, 2016 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-005 May 12, 2016 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for brivaracetam

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1452524 1690009-4 Sweden   Start Trial PRODUCT NAME: BRIVARACETAM; REG. NO/DATE: EU/1/15/1073 20150114
1452524 530 Finland   Start Trial
1452524 16C1001 France   Start Trial PRODUCT NAME: BRIVARACETAM; REGISTRATION NO/DATE: EU/1/15/1073 20160118
1452524 132016000045699 Italy   Start Trial PRODUCT NAME: BRIVARACETAM(BRIVIACT); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/15/1073, 20160118
1452524 C01452524/01 Switzerland   Start Trial PRODUCT NAME: BRIVARACETAM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65830 06.10.2016
1452524 2016/011 Ireland   Start Trial PRODUCT NAME: BRIVARACETAM; REGISTRATION NO/DATE: EU/1/15/1073 20160114
1452524 300815 Netherlands   Start Trial PRODUCT NAME: BRIVARACETAM; REGISTRATION NO/DATE: EU/1/15/1073 20160118
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Johnson and Johnson
Moodys
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.